Psychotropic drug and polypharmacy use among adolescents and young adults: Findings from the Finnish 1981 Nationwide Birth Cohort Study

Nordic Journal of Psychiatry

Volumn 66, Issue 5, 2012, Pages 336-342

  Gyllenberg, David ^a,b   Sourander, Andre ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Biomedicum 2C ^*  (Finland)

Author keywords

Antianxiety Drugs; Antidepressants; Antipsychotics; Psychopharmacoepidemiology

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; DRUG USE; FEMALE; FINLAND; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; ONSET AGE; POLYPHARMACY; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REGISTER; REIMBURSEMENT; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; MALE; MENTAL DISORDERS; POLYPHARMACY; PSYCHIATRY; PSYCHOTROPIC DRUGS; SEX FACTORS; YOUNG ADULT;

EID: 84865863734     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.644809     Document Type: Article

References (45)

1. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: A review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
2. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-56.
3. Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M. Psychotropic drug use among Icelandic children: A nationwide population-based study. J Child Adolesc Psychopharmacol 2009;19:757-64.
4. Martin A, Leslie D. Psychiatric inpatient, outpatient, and medication utilization and costs among privately insured youths, 1997-2000. Am J Psychiatry 2003;160:757-64.
5. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT. Psychotropic medication in children: A study from the Netherlands. Pediatrics 2001;108:E25.
6. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008;121:1002-9.
7. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004;158:753-9.
8. Clark AF. Incidences of new prescribing by British child and adolescent psychiatrists: A prospective study over 12 months. J Psychopharmacol 2004;18:115-20.
9. Barsky AJ. Forgetting, fabricating, and telescoping: The instability of the medical history. Arch Intern Med 2002;162:981-4.
10. Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: Past, present and future. J Psychopharmacol 2006;20(4 Suppl):85-94.
11. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in offi ce-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 2010;49:1001-10.
12. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in offi ce-based psychiatry. Arch Gen Psychiatry 2010;67:26-36.
13. Mancini J, Thirion X, Masut A, Saillard C, Pradel V, Romain F, et al. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf 2006;15:494-503.
14. Zito JM, Safer DJ, Berg LT, Janhsen K, Fegert JM, Gardner JF, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26.
15. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B. Patterns of neuroleptic drug prescription: A national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000;49:80-6.
16. Gilat Y, Ben-Dor DH, Magen A, Wolovick L, Vekslerchik M, Weizman A, et al. Trends in prescribing of psychotropic medications for inpatient adolescents in Israel: A 10 years retrospective analysis. Eur Psychiatry 2011;26:265-9.
17. Sourander A. Combined psychopharmacological treatment among child and adolescent inpatients in Finland. Eur Child Adolesc Psychiatry 2004;13:179-84.
18. Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol 2006;16:273-85.
19. Jordanova V, Maric NP, Alikaj V, Bajs M, Cavic T, Iosub D, et al. Prescribing practices in psychiatric hospitals in Eastern Europe. Eur Psychiatry 2010; Epub ahead of print Sep 7.
20. Gyllenberg D, Sourander A, Niemelä S, Helenius H, Sillanmäki L, Ristkari T, et al. Childhood predictors of use and costs of antidepressant medication by age 24 years: Findings from the Finnish nationwide 1981 birth cohort study. J Am Acad Child Adolesc Psychiatry 2011;50:406-15.
21. Almqvist F, Ikä heimo K, Kumpulainen K, Tuompo-Johansson E, Linna SL, Puura K, et al. Design and subjects of a Finnish epidemiological study on psychiatric disorders in childhood. Eur Child Adolesc Psychiatry 1999;8 Suppl 4:3-6.
22. Sourander A, Ronning J, Brunstein-Klomek A, Gyllenberg D, Kumpulainen K, NiemeläS, et al. Childhood bullying behavior and later psychiatric hospital and psychopharmacologic treatment: Findings from the Finnish 1981 birth cohort study. Arch Gen Psychiatry 2009;66:1005-12.
23. National Social Insurance Institution. Statistical Yearbook, the Social Insurance Institution. 2007; Available at: www.kela.fi/it/kelasto/kelasto.nsf/ alias/Vk-06-pdf. Accessed April 5, 2010.
24. Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatr Serv 2003;54:72-7.
25. Zito JM, Safer DJ. Recent child pharmacoepidemiological fi ndings. J Child Adolesc Psychopharmacol 2005;15:5-9.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Cox DR. Regression models and life-tables. J R Stat Soc Ser B (Methodological) 1972;34:187-220.
28. Autti-RämöI, Seppänen J, Raitasalo R, Martikainen JE, Sourander A. Increase in use of psychotropics among adolescents and young adults since the beginning of the 21st century. Suomen Lää kärilehti (Finnish Medical Journal) 2009;64:477-82.
29. Vitiello B, Zuvekas SH, Norquist GS. National estimates of antidepressant medication use among U.S. children, 1997-2002. J Am Acad Child Adolesc Psychiatry 2006;45:271-9.
30. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44:548-56.
31. Zoega H, Furu K, Halldorsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: A population-based comparison study. Acta Psychiatr Scand 2011;123:360-7.
32. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008;9:947-57.
33. Kessler RC, Olfson M, Berglund PA. Patterns and predictors of treatment contact after fi rst onset of psychiatric disorders. Am J Psychiatry 1998;155:62-9.
34. Autti-RämöI, Sourander A, Seppänen J, Martikainen JE. Use of antidepressants among 0-26 year olds in Finland during 1997-2007. Eur J Psychiat 2011;25:164-72.
35. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96.
36. Hoffman EJ, Mathew SJ. Anxiety disorders: A comprehensive review of pharmacotherapies. Mt Sinai J Med 2008;75:248-62.
37. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009;166:418-26.
38. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004;65:28-36.
39. Thase ME. Bipolar depression: Issues in diagnosis and treatment. Harv Rev Psychiatry 2005;13:257-71.
40. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11.
41. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother 2009;43:707-13.
42. Schwartz S, Diez Roux AV, Susser E. Causal explanation outside the black box. In: Susser E, Schwartz S, Morabia A, Bromet E, editors. Psychiatric epidemiology. New York: Oxford Scholarship Online Monographs; 2006. p. 441-61.
43. Fisher RL, Fisher S. Antidepressants for children. Is scientifi c support necessary? J Nerv Ment Dis 1996;184:99-102.
44. Sourander A. Risperidone for treatment of childhood schizophrenia. Am J Psychiatry 1997;154:1476.
45. Bryden KE, Carrey NJ, Kutcher SP. Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 2001;11:113-30.